{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T16:08:23Z","timestamp":1794672503360,"version":"4.9.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1038\/s41571-021-00487-z","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T11:03:41Z","timestamp":1615806221000},"page":"313-319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":110,"title":["COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials"],"prefix":"10.1038","volume":"18","author":[{"given":"Aakash","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Hegde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Schram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-7675","authenticated-orcid":false,"given":"Roman","family":"Groisberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Dragovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sant","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-7085","authenticated-orcid":false,"given":"Pashtoon M.","family":"Kasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert H.","family":"Loong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeseong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-3217","authenticated-orcid":false,"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-7911","authenticated-orcid":false,"given":"Ishwaria M.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6064-6837","authenticated-orcid":false,"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the COVID19 and Cancer Clinical Trials Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"487_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2020","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2020).","journal-title":"N. Engl. J. Med."},{"key":"487_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect. Dis. 21, 181\u2013192 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"487_CR4","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"487_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"487_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.019","author":"C Corti","year":"2021","unstructured":"Corti, C. & Curigliano, G. Commentary: SARS-CoV-2 vaccines and cancer patients. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.019 (2021).","journal-title":"Ann. Oncol."},{"key":"487_CR7","doi-asserted-by":"publisher","unstructured":"Desai, A. et al. Mortality in hospitalized patients with cancer and coronavirus disease 2019: a systematic review and meta-analysis of cohort studies. Cancer https:\/\/doi.org\/10.1002\/cncr.33386 (2020).","DOI":"10.1002\/cncr.33386"},{"key":"487_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/GO.20.00097","volume":"6","author":"A Desai","year":"2020","unstructured":"Desai, A., Sachdeva, S., Parekh, T. & Desai, R. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob. Oncol. 6, 557\u2013559 (2020).","journal-title":"JCO Glob. Oncol."},{"key":"487_CR9","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","volume":"395","author":"NM Kuderer","year":"2020","unstructured":"Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395, 1907\u20131918 (2020).","journal-title":"Lancet"},{"key":"487_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s43018-020-00129-w","volume":"1","author":"V Subbiah","year":"2020","unstructured":"Subbiah, V. A global effort to understand the riddles of COVID-19 and cancer. Nat. Cancer 1, 943\u2013945 (2020).","journal-title":"Nat. Cancer"},{"key":"487_CR11","first-page":"3033","volume":"136","author":"A Chari","year":"2020","unstructured":"Chari, A. et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood J. Am. Soc. Hematol. 136, 3033\u20133040 (2020).","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"487_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui, T. et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia 35, 485\u2013493 (2021).","journal-title":"Leukemia"},{"key":"487_CR13","doi-asserted-by":"publisher","unstructured":"Sharma, A. et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. https:\/\/doi.org\/10.1016\/S2352-3026(20)30429-4 (2021).","DOI":"10.1016\/S2352-3026(20)30429-4"},{"key":"487_CR14","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","volume":"323","author":"S Richardson","year":"2020","unstructured":"Richardson, S. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 323, 2052\u20132059 (2020).","journal-title":"JAMA"},{"key":"487_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1158\/2159-8290.CD-20-1817","volume":"11","author":"A Ribas","year":"2020","unstructured":"Ribas, A. et al. Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. Cancer Discov. 11, 233\u2013236 (2020).","journal-title":"Cancer Discov."},{"key":"487_CR16","unstructured":"Ong, M. B. H. Cancer groups urge CDC to prioritize cancer patients for COVID-19 vaccination. Cancer Letter https:\/\/cancerletter.com\/articles\/20210108_2\/ (2021)."},{"key":"487_CR17","unstructured":"Society for Immunotherapy of Cancer. SITC Statement on SARS-CoV-2 Vaccination and Cancer Immunotherapy. SIT Cancer https:\/\/www.sitcancer.org\/aboutsitc\/press-releases\/2020\/sitc-statement-sars-cov-2-vaccination-cancer-immunotherapy (2020)."},{"key":"487_CR18","unstructured":"National Comprehensive Cancer Network. Preliminary recommendations of the NCCN COVID-19 Vaccination Advisory Committee* Version 1.0 1\/22\/2021. NCCN https:\/\/www.nccn.org\/covid-19\/pdf\/COVID-19_Vaccination_Guidance_V1.0.pdf (2021)."},{"key":"487_CR19","unstructured":"SEOM. Posicionamiento y recomendaciones de seom en relacio\u0301 n con la campan\u0303a de vacunacio\u0301n frente ll Covid-19 en pacientes con c\u00e1ncer [Spanish]. Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica https:\/\/seom.org\/images\/Posicionamiento_SEOM_vacunacion_COVID19_pacientes_con_cancer.pdf (2021)."},{"key":"487_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.068","author":"MC Garassino","year":"2021","unstructured":"Garassino, M. C. et al. The ESMO call to action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.01.068 (2021).","journal-title":"Ann. Oncol."},{"key":"487_CR21","unstructured":"Centers for Disease Control and Prevention. CDC\u2019s COVID-19 Vaccine Rollout Recommendations. CDC https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/recommendations.html (2021)."},{"key":"487_CR22","unstructured":"Food and Drug Administration. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards. FDA https:\/\/www.fda.gov\/media\/136238\/download (2020)."},{"key":"487_CR23","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin, L. G. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 58, e44\u2013e100 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"487_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamaoncol.2020.5748","volume":"7","author":"ME Fleury","year":"2021","unstructured":"Fleury, M. E., Farner, A. M. & Unger, J. M. Association of the COVID-19 outbreak with patient willingness to enroll in cancer clinical trials. JAMA Oncol. 7, 131\u2013132 (2021).","journal-title":"JAMA Oncol."},{"key":"487_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10651","volume":"3","author":"JM Unger","year":"2020","unstructured":"Unger, J. M., Blanke, C. D., LeBlanc, M. & Hershman, D. L. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Netw. Open 3, e2010651 (2020).","journal-title":"JAMA Netw. Open"},{"key":"487_CR26","unstructured":"Food and Drug Administration. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. FDA https:\/\/www.fda.gov\/media\/136238\/download (2021)."},{"key":"487_CR27","unstructured":"European Medicines Agency. Implications of Coronavirus Disease (COVID-19) on Methodological Aspects of Ongoing Clinical Trials. EMA https:\/\/www.ema.europa.eu\/en\/implications-coronavirus-disease-covid-19-methodological-aspects-ongoing-clinical-trials (2021)."},{"key":"487_CR28","doi-asserted-by":"publisher","unstructured":"Desai, A. & Subbiah, V. COVID-19 pandemic and cancer clinical trial pandemonium: finding the silver lining. J. Immunoth. Precision Oncol. https:\/\/doi.org\/10.36401\/JIPO-20-X7 (2020).","DOI":"10.36401\/JIPO-20-X7"},{"key":"487_CR29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36462","volume":"4","author":"M Karmakar","year":"2021","unstructured":"Karmakar, M., Lantz, P. M. & Tipirneni, R. Association of social and demographic factors With COVID-19 incidence and death rates in the us. JAMA Netw. Open 4, e2036462 (2021).","journal-title":"JAMA Netw. Open"},{"key":"487_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01240-w","author":"AAM van der Veldt","year":"2021","unstructured":"van der Veldt, A. A. M. et al. COVID-19 vaccination: the VOICE for patients with cancer. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01240-w (2021).","journal-title":"Nat. Med."},{"key":"487_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41591-021-01230-y","volume":"27","author":"JH Kim","year":"2021","unstructured":"Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials. Nat. Med. 27, 205\u2013211 (2021).","journal-title":"Nat. Med."},{"key":"487_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00017-6","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(21)00017-6 (2021).","journal-title":"Lancet Oncol."},{"key":"487_CR33","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.3389\/fimmu.2017.01472","volume":"8","author":"M Castells","year":"2017","unstructured":"Castells, M. Drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: the role of desensitizations. Front. Immunol. 8, 1472 (2017).","journal-title":"Front. Immunol."},{"key":"487_CR34","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/cncr.30468","volume":"123","author":"B Keam","year":"2017","unstructured":"Keam, B. et al. Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. Cancer 123, 841\u2013848 (2017).","journal-title":"Cancer"},{"key":"487_CR35","unstructured":"Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. CDC https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/clinical-considerations.html (2021)."},{"key":"487_CR36","unstructured":"Society of Breast Imaging Patient Care and Delivery Committee. SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination. SBI Online https:\/\/www.sbi-online.org\/Portals\/0\/Position%20Statements\/2021\/SBI-recommendations-for-managing-axillary-adenopathy-post-COVID-vaccination.pdf (2021)."},{"key":"487_CR37","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.25604","author":"CE Edmonds","year":"2021","unstructured":"Edmonds, C. E., Zuckerman, S. P. & Conant, E. F. Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of coronavirus disease (COVID-19) vaccination. Am. J. Roentgenol. https:\/\/doi.org\/10.2214\/AJR.21.25604 (2021).","journal-title":"Am. J. Roentgenol."},{"key":"487_CR38","unstructured":"Centers for Disease Control and Prevention. COVID-19 Vaccines and Allergic Reactions. CDC https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/allergic-reaction.html (2021)."},{"key":"487_CR39","unstructured":"World Health Organization. Coronavirus Disease (COVID-19): Vaccine Access and Allocation. WHO https:\/\/www.who.int\/news-room\/q-a-detail\/coronavirus-disease-(covid-19)-vaccine-access-and-allocation (2020)."},{"key":"487_CR40","unstructured":"SWOG. MEMORANDUM- General Guidance for SWOG Clinical Trials and COVID-19 Vaccine. SWOG https:\/\/www.swog.org\/sites\/default\/files\/docs\/2021-01\/COVID%20memo%202-1-2021%20%20Broadcast.pdf (2021)."},{"key":"487_CR41","unstructured":"American Society of Clinical Oncology. COVID-19 Vaccine & Patients with Cancer. ASCO https:\/\/www.asco.org\/asco-coronavirus-resources\/covid-19-patient-care-information\/covid-19-vaccine-patients-cancer (2020)."}],"updated-by":[{"DOI":"10.1038\/s41571-021-00503-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000}}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00487-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41571-021-00487-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:44:29Z","timestamp":1684619069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-021-00487-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1038\/s41571-021-00487-z","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41571-021-00503-2","asserted-by":"object"}]},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"assertion":[{"value":"16 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41571-021-00503-2","URL":"https:\/\/doi.org\/10.1038\/s41571-021-00503-2","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F.G. has served as a compensated consultant or received honoraria from Agios, Amgen, Ariad\/Takeda, Array Biopharma, AstraZeneca, Blueprint, Bristol-Myers Squibb (BMS), EMD Serono, Genentech\/Roche, Gilead, GlydeBio, Incyte, Loxo Oncology\/Lilly, Merck, Mirati, Novartis, Oncorus, Pfizer and Regeneron; has received research support from Ariad\/Takeda, Genentech\/Roche and Novartis; institutional research support from Adaptimmune, Alexo, Array Biopharma, Blueprint, BMS, Jounce, Merck, Moderna, Novartis and Tesaro; and has an immediate family member who is an employee of Ironwood Pharmaceuticals. G.C. has served on advisory boards for AstraZeneca, Daiichi Sankyo, Ellipsis, Genomic Health, Lilly, Novartis, Roche and Veracyte. S.V.L. has served on advisory boards and\/or consulted for Amgen, AstraZeneca, Beigene, Blueprint, BMS, Daiichi Sankyo, G1 Therapeutics, Genentech, Guardant Health, Inivata, Janssen, Jazz, Lilly, Merck, PharmaMar, Pfizer, Regeneron and Takeda; and declares research grants (to his institution) from Alkermes, AstraZeneca, Bayer, Blueprint, BMS, Corvus, Genentech, Lilly, Lycera, Merck, Merus, Pfizer, Rain, RAPT, Spectrum and Turning Point Therapeutics. B.H. reports research funding (to his institution) from AbbVie, Advaxis, Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Elevation, GlaxoSmithKline, Lilly, Merck, Mirati, Novartis, and Pfizer; and advisory boards consulting roles for Amgen, Apollomics, AstraZeneca, BMS, Boehringer Ingelheim, Guardant Health, Merck, Novartis, Pfizer and TPT. R.G. has received honoraria from Regeneron. E.G. has received honoraria for advisory boards, meetings and\/or lectures from Adacap, BMS, Celgene, Eisai, Eusa Pharma, Ipsen, Lexicon, MSD, Novartis, Pfizer, Pierre Fabre, Roche and Sanofi-Genzyme; and unrestricted research grants from AstraZeneca, Ipsen, Lexicon, MTEM\/Threshold, Pfizer and Roche. T.D. declares clinical research support\/grants (to his institution) from BMS, Lilly, Exelixis, Holystone, Mirati, Novacure, Pharmacyclics and RAPT Pharma. M.M. has been a consultant for AstraZeneca, Dispersol and Strata Oncology; and has received speaker\u2019s bureau fee from Astellas, AstraZeneca, BMS, Eisai, Janssen, Merck and Seagen N.A. has served as a consultant to Astellas, AstraZeneca, Aveo, Bayer, BMS, Calithera, Clovis, Eisai, Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics and Seattle Genetics. S.K. has served as a consultant for Foundation Medicine; has received a speaker\u2019s fee from Roche; has served on advisory boards for Pfizer; and has received research funding from ACT Genomics, Konica Minolta, OmniSeq and Sysmex. P.M.K. has served as a consultant and\/or advisory board member for Foundation Medicine, Ipsen, Natera, QED and Taiho Oncology; and declares clinical trials involvement and\/or funding from AstraZeneca, Boston Scientific and TerSera. H.P. declares research funding\/grant support for clinical trials (to her institution) from Ambrx, Amgen, Aprea Therapeutics, Array BioPharma, Bayer, BeiGene, BJ Bioscience, BMS, Daiichi Sankyo, Elicio Therapeutics, Lilly, EMD Serono, Genentech, Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Hoffman-LaRoche, Hutchison MediPharma, ImmuneOncia Therapeutics, Incyte, Jounce, Mabspace Biosciences, MacroGenics, MedImmune, Medivation, Merck, Millennium, Mirati Therapeutics, Novartis Pharmaceuticals, Oncologie, Pfizer, PsiOxus Therapeutics, Puma Biotechnology, Regeneron Pharmaceuticals, Seattle Genetics, Synermore Biologics, Taiho Pharmaceutical, TopAlliance Biosciences, Turning Point Therapeutics, Vedanta Biosciences, Vertex Pharmaceuticals and Xencor. T.K.C. reports institutional and personal research support from Alexion, Analysis Group, AstraZeneca, Bayer, BMS\/ER Squibb and Sons, Calithera, Cerulean, Corvus, Eisai, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Ipsen, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Roche, Roche Products, Sanofi\/Aventis, Takeda and Tracon; honoraria from Alexion, American Society of Medical Oncology, Analysis Group, AstraZeneca, Bayer, BMS\/ER Squibb and Sons, Cerulean, Clinical Care Options, Corvus, Eisai, EMD Serono, Exelixis, F. Hoffmann-La Roche, Foundation Medicine, Genentech, GlaxoSmithKline, Harborside Press, Heron Therapeutics, Ipsen, <i>Kidney Cancer Journal<\/i>, <i>Lancet Oncology<\/i>, Lilly Oncology, L-path, Merck, Michael J. Hennessy (MJH) Associates (Healthcare Communications Company with several brands such as OnClive, PeerView and PER), Navinata Healthcare, NCCN, <i>New England Journal of Medicine<\/i>, Novartis, Peloton, Pfizer, Platform Q, Prometheus Labs, Research to Practice, Roche, Roche Products, Sanofi\/Aventis and Up-to-Date; consulting or advisory roles with Alexion, Analysis Group, AstraZeneca, Bayer, BMS\/ER Squibb and Sons, Cerulean, Corvus, Eisai, EMD Serono, Exelixis, Foundation Medicine, Genentech, GlaxoSmithKline, Heron Therapeutics, Ipsen, Lilly, Lilly Ventures, Merck, NCCN, Novartis, Peloton, Pfizer, Pionyr, Prometheus Labs, Roche, Sanofi\/Aventis, Tempest and Up-to-Date; stock\/option ownership in Pionyr and Tempest; present or past leadership roles as Director of GU Oncology Division at the Dana-Farber Cancer Institute (DFCI) and past President of Medical Staff at DFCI, a member of NCCN Kidney panel and the GU Steering Committee, past chairman of the Kidney Cancer Association Medical and Scientific Steering Committee, a member of the KidneyCan Advisory board, Kidney Cancer Research Summit co-chair (2019\u2013present); patents, royalties or other intellectual properties related to biomarkers of immune checkpoint blockers and circulating free methylated DNA; and travel, accommodation, expenses, in relation to consulting, advisory roles or honoraria. N.P. serves on the ASH Communications and ASCO Leukemia advisory panels; has received consultant fees from Blueprint, BMS, ImmunoGen, Pacylex Pharmaceuticals; grants from Affymetrix and the Sagerstrong Foundation; honoraria from AbbVie, Blueprint, Celgene, DAVA Oncology, Incyte, LFB Biotechnologies, MustangBio, Novartis, Roche Diagnostics, Springer Science & Business Media and Stemline Therapeutics; research support from AbbVie, Affymetrix, Celgene, Cellectis, Daiichi Sankyo, Novartis, Plexxikon, Samus Therapeutics and Stemline Therapeutics; and travel support from AbbVie, Celgene, DAVA Oncology, MustangBio and Stemline Therapeutics. V.S. declares research funding\/grant support for clinical trials (to his institution) from AbbVie, Agensys, Alfa-Sigma, Altum, Amgen, Bayer, Berghealth, Blueprint, Boston Biomedical, Boston Pharmaceuticals, D3, Dragonfly Therapeutics, Exelixis, Fujifilm, Idera Pharma, Incyte, Inhibrx, Loxo oncology, MedImmune, Multivir, NCCN, Novartis, Pharmamar, Pfizer, Takeda and Turning Point Therapeutics; has received travel funding from ASCO, ESMO, Helsinn, Incyte, Novartis and Pharmamar; and has served on advisory boards for AstraZeneca\/MedImmune, Helsinn, Incyte, Loxo Oncology\/Lilly, Novartis, QED Pharma, R-Pharma US and Signant Health. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}